HUP0000547A2 - Cinkmentes inzulinkristályok pulmonáris kompozíciókhoz - Google Patents

Cinkmentes inzulinkristályok pulmonáris kompozíciókhoz

Info

Publication number
HUP0000547A2
HUP0000547A2 HU0000547A HUP0000547A HUP0000547A2 HU P0000547 A2 HUP0000547 A2 HU P0000547A2 HU 0000547 A HU0000547 A HU 0000547A HU P0000547 A HUP0000547 A HU P0000547A HU P0000547 A2 HUP0000547 A2 HU P0000547A2
Authority
HU
Hungary
Prior art keywords
free insulin
crystals
insulin crystals
zinc free
pulmonary
Prior art date
Application number
HU0000547A
Other languages
English (en)
Inventor
Svend Havelund
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of HUP0000547A2 publication Critical patent/HUP0000547A2/hu
Publication of HUP0000547A3 publication Critical patent/HUP0000547A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Atalálmány cinkmentes inzűlinkristályőkkal főglalkőzik, amelykristályők átmérője 10mm alatt van. Anevezett kristályők az inzűlinpűlmőnáris beadására alkalmasak. Ezeknek a kristályőknak kisebb ahajlaműk arra, hőgy aggregátűmőkká asszőciálódjanak a száraz pőrban. ŕ
HU0000547A 1997-03-20 1998-03-20 Zinc free insulin crystals for use in pulmonary compositions HUP0000547A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK31797 1997-03-20

Publications (2)

Publication Number Publication Date
HUP0000547A2 true HUP0000547A2 (hu) 2000-08-28
HUP0000547A3 HUP0000547A3 (en) 2002-11-28

Family

ID=8092195

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000547A HUP0000547A3 (en) 1997-03-20 1998-03-20 Zinc free insulin crystals for use in pulmonary compositions

Country Status (17)

Country Link
US (2) US20070093411A1 (hu)
EP (2) EP1005490B1 (hu)
JP (1) JP3764174B2 (hu)
KR (1) KR20000076419A (hu)
CN (1) CN1259142A (hu)
AT (1) ATE321783T1 (hu)
AU (1) AU742591B2 (hu)
BR (1) BR9808285A (hu)
CA (1) CA2283705A1 (hu)
DE (1) DE69834028T2 (hu)
ES (1) ES2260832T3 (hu)
HU (1) HUP0000547A3 (hu)
IL (1) IL131796A0 (hu)
NO (1) NO994520D0 (hu)
PL (1) PL335777A1 (hu)
RU (1) RU2198181C2 (hu)
WO (1) WO1998042749A1 (hu)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2306477T3 (es) 1997-09-05 2008-11-01 Altus Pharmaceuticals Inc. Cristales de glicoproteina reticulados por carbohidratos.
US6500933B1 (en) 1997-09-05 2002-12-31 Altus Biologics Inc. Methods of preparing carbohydrate crosslinked glycoprotein crystals
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
WO1999055310A1 (en) * 1998-04-27 1999-11-04 Altus Biologics Inc. Stabilized protein crystals, formulations containing them and methods of making them
AU757991B2 (en) * 1998-04-27 2003-03-13 Altus Pharmaceuticals, Inc. Stabilized protein crystals, formulations containing them and methods of making them
DE19903125B4 (de) * 1999-01-27 2006-01-05 Sanofi-Aventis Deutschland Gmbh Verfahren zur Trocknung von Kristallen von Insulin oder Insulinanaloga
JP2002543092A (ja) * 1999-04-27 2002-12-17 イーライ・リリー・アンド・カンパニー 肺投与用インスリン結晶
GB0011807D0 (en) * 2000-05-16 2000-07-05 Quadrant Holdings Cambridge Formulation for inhalation
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US7193035B2 (en) 2002-10-29 2007-03-20 Sanofi-Aventis Deutschland Gmbh Crystals of insulin analogs and processes for their preparation
DE10250297A1 (de) * 2002-10-29 2004-05-19 Aventis Pharma Deutschland Gmbh Kristalle von Insulinanaloga und Verfahren zu ihrer Herstellung
EP2264065B1 (en) * 2003-08-05 2017-03-08 Novo Nordisk A/S Novel insulin derivatives
CA2553392A1 (en) 2004-01-16 2005-08-11 Biodel Inc Sublingual drug delivery device
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
KR100798333B1 (ko) * 2005-08-03 2008-01-28 고려대학교 산학협력단 락토오스 운반체와 혼합건조된 폐 전달용 인슐린미세결정분말
EP3228320B1 (de) 2008-10-17 2019-12-18 Sanofi-Aventis Deutschland GmbH Kombination von einem insulin und einem glp-1-agonisten
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
CN102471368A (zh) * 2009-08-11 2012-05-23 拜康有限公司 色谱方法及其纯化的化合物
UY33025A (es) 2009-11-13 2011-06-30 Sanofi Aventis Deustschland Gmbh Composicion farmaceutica que comprende un agonista de glp-1 metionina
AR080669A1 (es) 2009-11-13 2012-05-02 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina
MX339614B (es) 2010-08-30 2016-06-02 Sanofi - Aventis Deutschland GmbH Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
RU2650616C2 (ru) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
MX2017000027A (es) * 2014-07-08 2017-05-01 Amphastar Pharmaceuticals Inc Insulina micronizada, analogos de insulina micronizada y metodos para fabricarlos.
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN104761632A (zh) * 2015-04-14 2015-07-08 珠海联邦制药股份有限公司 一种地特胰岛素结晶的制备方法及应用
CN106117345B (zh) * 2015-05-05 2020-11-24 宜昌东阳光长江药业股份有限公司 一种制备甘精胰岛素结晶的方法
US20180244743A1 (en) 2015-08-25 2018-08-30 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
CN108026156A (zh) 2015-08-25 2018-05-11 诺和诺德股份有限公司 新型胰岛素衍生物及其医学用途
EP3341403B1 (en) 2015-08-25 2022-01-05 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
US10322168B2 (en) 2016-01-07 2019-06-18 Amphastar Pharmaceuticals, Inc. High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same
CN106749616B (zh) * 2016-12-19 2021-09-03 华润昂德生物药业有限公司 B30位苏氨酸缺失人胰岛素晶体的制备方法
CN109957001B (zh) * 2017-12-26 2022-11-18 甘李药业股份有限公司 甘赖脯胰岛素结晶的制备方法
PL238016B1 (pl) * 2018-07-06 2021-06-28 Bioton Spolka Akcyjna Krystaliczna, bezcynkowa postać insuliny glargine i sposób jej otrzymywania
RS65822B1 (sr) 2019-12-11 2024-09-30 Novo Nordisk As Novi insulinski analozi i njihova upotreba

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719655A (en) * 1969-12-05 1973-03-06 Lilly Co Eli Process for the crystallization of the ammonium and alkali metal salts in insulin
DE3327928A1 (de) * 1983-08-03 1985-02-21 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von insulin-derivaten
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
PL178466B1 (pl) * 1993-09-17 2000-05-31 Novo Nordisk As Pochodna insuliny i kompozycja farmaceutyczna do leczenia cukrzycy
KR100419037B1 (ko) * 1994-03-07 2004-06-12 넥타르 테라퓨틱스 폐를통한인슐린의전달방법및그조성물
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
US5700904A (en) * 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
US6310038B1 (en) * 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität

Also Published As

Publication number Publication date
AU6612098A (en) 1998-10-20
PL335777A1 (en) 2000-05-22
KR20000076419A (ko) 2000-12-26
US20090311326A9 (en) 2009-12-17
EP1627642A3 (en) 2006-04-19
IL131796A0 (en) 2001-03-19
US20070292520A1 (en) 2007-12-20
DE69834028D1 (de) 2006-05-18
ATE321783T1 (de) 2006-04-15
US20070093411A1 (en) 2007-04-26
CN1259142A (zh) 2000-07-05
EP1627642A2 (en) 2006-02-22
NO994520L (no) 1999-09-17
CA2283705A1 (en) 1998-10-01
HUP0000547A3 (en) 2002-11-28
WO1998042749A1 (en) 1998-10-01
RU2198181C2 (ru) 2003-02-10
DE69834028T2 (de) 2006-12-07
NO994520D0 (no) 1999-09-17
EP1005490A1 (en) 2000-06-07
EP1005490B1 (en) 2006-03-29
ES2260832T3 (es) 2006-11-01
JP3764174B2 (ja) 2006-04-05
AU742591B2 (en) 2002-01-10
BR9808285A (pt) 2000-05-16
JP2001506272A (ja) 2001-05-15

Similar Documents

Publication Publication Date Title
HUP0000547A2 (hu) Cinkmentes inzulinkristályok pulmonáris kompozíciókhoz
TR200101961T2 (tr) 1,2-halkalı kinolin türevleri
EP0291969A3 (en) Tetrazole intermediates to antihypertensive compounds
ES2162676T3 (es) Derivados de fenileno sustituidos en meta y su uso como antagonistas o inhibidores de integrina alfav,beta3.
EP1046394A3 (en) Novel compositions useful for delivering compounds into a cell
MX9305798A (es) Composiciones de lapiz labial humedecedor.
BRPI9715334B8 (pt) agentes estrogênicos e composição farmacêutica compreendendo os mesmos.
NO20041980L (no) Foring for rettet ladning
HUP0001293A1 (hu) Heterociklusos vegyületek és ezeket tartalmazó gyógyászati készítmények béta-amiloid-peptidek gátlására
MY116845A (en) New 19-nor-pregnene derivatives
ES8609279A1 (es) Un procedimiento para la preparacion de nuevos derivados de 1,2,3-triazol.
BR9709062A (pt) Composto, composição farmacêutica, e, uso de um composto.
TR200200981T2 (tr) Farmasötik bileşim terkipleri
EP0318084A3 (en) Benzoheterazoles
WO1991019475A1 (en) Quinolinyl-benzoheterobicyclic derivatives as antagonists of leukotriene d¿4?
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
TR200200125T2 (tr) Yeni aminotiyazol türevleri, bunların hazırlanması ve bunları içeren farmasötik kompozisyonlar.
BG105847A (en) Calcilytic compounds
ES2191343T3 (es) Derivado de ribonucleoxido y su procedimiento de preparacion.
EP0952159A3 (en) Use of somatostatin derivatives and/or of phenylhydrazone derivatives as antinflammatory or analgetic agents
TR200101083T2 (tr) (7alfa,17alfa)-17-hidroksi- 7-metil-19-nor-17-pregn-5 (10)-en-20-in-3-on içeren yüksek saflıkta bileşim.
BR0011261A (pt) Composição oral compreendendo perlita, e, uso de perlita
ES2190533T3 (es) Derivados de tropano utilizables en particular para la deteccion in vivo de transportadores de dopamina.
BG103502A (en) Heterocyclic derivatives of carboxylic acids, their preparation and application as endothelial receptor antagonists
BG103412A (en) Stabilized pharmaceutical compositions based on chinupristine and dalfopristine and their preparation